4Q EARNINGS: Pfizer investors look ahead to new cancer drug, business split
This article was originally published in Scrip
Two questions dominated Pfizer’s fourth-quarter conference call: How quickly is the company going to shed its off-patent drugs and what’s the confidence level for an experimental cancer treatment, palbociclib?
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.